Skip to main content
. 2021 May 18;12:2928. doi: 10.1038/s41467-021-23250-5

Fig. 7. In vivo therapeutic efficacy of siRNA/Ap-CS against malignant tumor in A549 NSCLC xenograft murine model.

Fig. 7

a Tumor growth curves during treating with siPlk1 delivered by different formulations. The arrows represent the intravenous injections via tail vein. The error bar represents the standard deviation (SD). The measured data are expressed as the means ± SD (n = 3). b Images of tumor-bearing mouse and corresponding harvested tumors 14 days after treatment with different siPlk1-encapsulated formulations. c Hematoxylin and eosin (H&E) staining-based histological images of tumor sections obtained from the same model mice as b. The histological examination was performed three times independently with similar results. **P < 0.01, ***P < 0.001, ****P < 0.0001, two-tailed unpaired t test.